Current Alzheimer Research

metrics 2024

Uniting Researchers for a Brighter Future in Neurology

Introduction

Current Alzheimer Research is a pivotal journal dedicated to advancing knowledge in the field of neurology, with a particular focus on Alzheimer's disease and related neurodegenerative disorders. Published by BENTHAM SCIENCE PUBL LTD, this journal contributes to the growing body of literature aimed at bridging the gap between clinical research and practical application. Operating out of the United Arab Emirates, it has established itself as a reputable source for interdisciplinary research and clinical studies, reflecting its category quartiles ranking of Q3 in both Neurology and Clinical Neurology as of 2023. The journal, which spans from 2004 to 2024, provides scientists, clinicians, and students with up-to-date research findings while fostering an environment of knowledge exchange. Researchers are encouraged to submit their work, share insights, and engage with the latest discoveries that aim to enhance understanding and treatment strategies in Alzheimer’s disease, thereby addressing one of the most pressing challenges in neuroscience today.

Metrics 2024

SCIMAGO Journal Rank0.58
Journal Impact Factor1.80
Journal Impact Factor (5 years)2.90
H-Index103
Journal IF Without Self1.80
Eigen Factor0.00
Normal Eigen Factor0.63
Influence0.64
Immediacy Index0.40
Cited Half Life7.90
Citing Half Life8.30
JCI0.43
Total Documents1917
WOS Total Citations4773
SCIMAGO Total Citations19636
SCIMAGO SELF Citations809
Scopus Journal Rank0.58
Cites / Document (2 Years)1.80
Cites / Document (3 Years)2.15
Cites / Document (4 Years)2.62

Metrics History

Rank 2024

Scopus

Neurology (clinical) in Medicine
Rank #197/400
Percentile 50.75
Quartile Q2
Neurology in Neuroscience
Rank #102/192
Percentile 46.88
Quartile Q3

IF (Web Of Science)

CLINICAL NEUROLOGY
Rank 188/277
Percentile 32.30
Quartile Q3
NEUROSCIENCES
Rank 242/310
Percentile 22.10
Quartile Q4

JCI (Web Of Science)

CLINICAL NEUROLOGY
Rank 218/278
Percentile 21.58
Quartile Q4
NEUROSCIENCES
Rank 268/310
Percentile 13.55
Quartile Q4

Quartile History

Similar Journals

BIOFACTORS

Elevating Research Standards in Biochemistry and Medicine
Publisher: WILEYISSN: 0951-6433Frequency: 6 issues/year

BIOFACTORS, an esteemed journal published by Wiley, serves as a pivotal resource in the fields of Biochemistry, Clinical Biochemistry, and Molecular Medicine. With ISSN 0951-6433 and E-ISSN 1872-8081, the journal has established its reputation since its inception in 1988, showcasing a rich history of scientific inquiry and innovation. Recognized for its high academic standards, it currently holds a Q1 ranking in key categories, including Biochemistry and Medicine (miscellaneous), and ranks in the top 10% for Clinical Biochemistry according to Scopus metrics, reflecting its impact and influence in the scientific community. Although it does not offer Open Access, BIOFACTORS provides researchers the opportunity to publish and disseminate high-quality studies that advance our understanding of biological factors and their clinical implications. The journal actively encourages contributions that bridge the gap between laboratory findings and clinical applications, making it a vital platform for both seasoned researchers and emerging scholars in the life sciences.

FOLIA NEUROPATHOLOGICA

Advancing the frontiers of neuropathology research.
Publisher: TERMEDIA PUBLISHING HOUSE LTDISSN: 1641-4640Frequency: 4 issues/year

FOLIA NEUROPATHOLOGICA is a distinguished Open Access journal specializing in the fields of Neurology and Pathology, published by the reputable TERMEDIA PUBLISHING HOUSE LTD. With an ISSN of 1641-4640 and E-ISSN 1509-572X, this journal has been a vital resource for the dissemination of high-quality research since its inception in 1994. Covering a broad spectrum of topics within neuropathology, the journal emphasizes clinical findings and forensic implications, making it an essential platform for healthcare professionals, researchers, and students alike. With impressive impact factors positioning it in the Q3 category for both Neurology (clinical) and Pathology and Forensic Medicine, FOLIA NEUROPATHOLOGICA occupies a significant place among its peers, ranked within the 36th to 46th percentiles on Scopus. Scholars can benefit from the Open Access model implemented since 2005, ensuring wide accessibility and distribution of critical research outputs aimed at advancing both clinical practices and academic knowledge. Based in Poland, at KLEEBERGA 2, POZNAN 61-615, this journal continues to shape the discourse in neuropathology and related fields.

Alzheimers Research & Therapy

Exploring breakthroughs in cognitive neuroscience and neurology.
Publisher: BMCISSN: Frequency: 1 issue/year

Alzheimer's Research & Therapy is a leading peer-reviewed journal published by BMC, dedicated to advancing our understanding of Alzheimer's disease and other neurodegenerative disorders. As an Open Access journal since 2009, it ensures that vital research findings are freely accessible to the global community, facilitating collaboration and innovation in the field. The journal's commitment to quality is evident in its impressive impact factor and its prestigious ranking in the Q1 quartile across multiple categories including Cognitive Neuroscience and Neurology. With a Scopus rank placing it in the top tier of both Neuroscience and Neurology disciplines, Alzheimer's Research & Therapy serves as a crucial platform for researchers, clinicians, and students who seek to contribute to the fight against Alzheimer's and related disorders. The journal covers a wide range of topics and actively encourages submissions that explore therapeutic strategies and innovative research methodologies, enriching the scientific dialogue in this vital area of health.

JAMA Neurology

Transforming Understanding of Neurology through Open Access
Publisher: AMER MEDICAL ASSOCISSN: 2168-6149Frequency: 12 issues/year

JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.

Frontiers in Aging Neuroscience

Bridging Science and Aging for Cognitive Excellence.
Publisher: FRONTIERS MEDIA SAISSN: 1663-4365Frequency: 1 issue/year

Frontiers in Aging Neuroscience, published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to the field of aging neuroscience, with its ISSN being 1663-4365. Since its inception in 2009, this journal has provided a platform for researchers to disseminate their findings on the neurological aspects of aging, addressing critical issues that impact cognition and overall brain health in the elderly population. With a commendable 2023 impact factor, the journal ranks in the Q2 category in both Aging and Cognitive Neuroscience, positioning it among the top-tier publications in these fields. Notably, it is recognized within Scopus, ranking #32 out of 115 in Neuroscience (Cognitive Neuroscience) and #20 out of 38 in the Aging sector, with corresponding percentiles of 72nd and 48th, respectively. As an open-access journal, it promotes unrestricted access to research findings, fostering collaboration and innovation among the academic community. Researchers, professionals, and students alike can explore cutting-edge studies that contribute to understanding the complexities of neurological aging and work towards improving cognitive health in an aging society.

ACTA NEUROLOGICA SCANDINAVICA

Advancing Neurological Insights
Publisher: WILEYISSN: 0001-6314Frequency: 12 issues/year

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

LANCET NEUROLOGY

Transforming Clinical Practice Through Research
Publisher: ELSEVIER SCIENCE INCISSN: 1474-4422Frequency: 12 issues/year

The Lancet Neurology is a premier academic journal published by Elsevier Science Inc, specializing in the field of neurology. With a robust impact factor that signifies its authoritative presence, it consistently ranks in the Q1 category for clinical neurology according to the 2023 standards, positioning itself as the leading journal in its domain, ranking #1 out of 400 in Scopus' neurology rankings and placing in the 99th percentile. Since its establishment in 2002, it has provided a vital platform for disseminating innovative research and clinical advances related to neurological disorders. The journal’s precise focus includes cutting-edge studies on neurodegenerative diseases, stroke, epilepsy, and neuroimaging, which are essential for advancing clinical practice and improving patient outcomes. While it does not offer open access, readers can find high-impact research published monthly, making it indispensable for practitioners, researchers, and students eager to stay at the forefront of neurological science.

Neuropsychiatric Disease and Treatment

Exploring the Frontiers of Neuropsychiatric Science
Publisher: DOVE MEDICAL PRESS LTDISSN: Frequency: 1 issue/year

Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.

Neurodegenerative Disease Management

Innovating Strategies for Neurodegenerative Challenges
Publisher: FUTURE MEDICINE LTDISSN: 1758-2024Frequency: 6 issues/year

Neurodegenerative Disease Management is a distinguished journal published by FUTURE MEDICINE LTD, focusing on the pivotal issues surrounding the management of neurodegenerative diseases. Since its inception in 2014, this journal has emerged as a significant resource within the fields of medicine and neurology, currently holding a respected position with a Q2 category ranking in Medicine (miscellaneous) and Q3 in Neurology (clinical) for 2023. With an ISSN of 1758-2024 and E-ISSN 1758-2032, the journal provides a platform for the dissemination of innovative research, clinical practices, and advancements in treatment strategies for conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. The journal is particularly committed to enhancing knowledge sharing among researchers, health professionals, and students, contributing to the collective effort in combatting neurodegenerative diseases. Though not open access, its articles are meticulously curated to ensure high-quality, impactful contributions to the field, making it an essential reference for those engaged in neurology and related disciplines.

Aging and Disease

Illuminating pathways to better health in aging.
Publisher: INT SOC AGING & DISEASEISSN: 2152-5250Frequency: 6 issues/year

Aging and Disease is a leading open-access journal published by the International Society on Aging and Disease, dedicated to advancing the understanding of aging and its associated diseases. Since its inception in 2010, the journal has established itself as a vital resource for researchers and practitioners in the fields of Geriatrics, Neurology, Cell Biology, and Pathology. With an impressive Q1 ranking across multiple categories and a robust position in Scopus rankings, including ranks in the top 3% in Geriatrics and Gerontology, it showcases high-quality research that addresses the complexities of aging processes. Each issue presents original articles, reviews, and insights aimed at improving health outcomes for the aging population. The open-access model ensures that valuable research findings are readily available to a global audience, fostering collaboration and innovation. As a go-to publication for scholars, healthcare professionals, and students, Aging and Disease significantly contributes to the multidisciplinary dialogue surrounding aging and its health implications.